ArticleTranslational andrology and urology2026
Bioinformatics analysis and experimental validation confirm COL6A3 as a promising target for renal cell carcinoma therapy.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kidney cancer is a prevalent urogenital malignancy, with renal cell carcinoma (RCC) accounting for over 90% of cases. Despite the rising incidence and the primary use of surgery as a treatment, mortality rates remain high, highlighting an urgent need for effective therapeutic strategies. Collagen VI alpha 3 (COL6A3), an isoform of collagen VI, is known to play a key role in the pathogenesis of diabetes and obesity. However, its expression pattern, clinicopathological features, prognostic significance, and immune-related associations in RCC remain largely unexplored. Therefore, the aim of this study is to elucidate the biological function of COL6A3 in RCC, specifically exploring its role in the tumor immune microenvironment and the PI3K-AKT signaling pathway, to identify a novel therapeutic target. Methods: We investigated COL6A3 expression and associated clinical outcomes using online databases, including Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), and University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN), along with multiple R packages. Furthermore, tumor immune infiltration and immunotherapeutic responses, and chemotherapeutic sensitivities were computationally evaluated. Subsequently, biological functions were validated using Western blot, quantitative real-time polymerase chain reaction (qRT-PCR), immunohistochemistry (IHC), Cell Counting Kit-8 (CCK-8), colony formation, 5-ethynyl-2'-deoxyuridine (EdU), wound healing, and Transwell assays, and Results: Our analysis revealed that COL6A3 expression was significantly upregulated in RCC tissues. High COL6A3 expression correlated with poor clinical prognosis and malignant progression. Conclusions: These findings indicate that COL6A3 acts as an oncogenic driver and a potential immunosuppressive indicator, serving as a novel prognostic biomarker and therapeutic target. This dual role offers new insights for stratifying patients and developing tailored immunotherapeutic and targeted therapies for renal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.